Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.61 |
| ▸ | THRA | P10827 | 3/20 | 0.60 |
| ▸ | THRB | P10828 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | RARB | P10826 | 3/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2356406 | 1.00 | MAPT (0.66) | MAPTTP53TSHRPLA2G4BTHRA | |
| SCHEMBL2350770 | 0.98 | MAPT (0.68) | MAPTTP53TSHRPLA2G4BTHRA | |
| SCHEMBL2350431 | 0.95 | MAPT (0.72) | MAPTTP53TSHRPLA2G4BRAB9A | |
| SCHEMBL12113908 | 0.94 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BRAB9A | |
| SCHEMBL21908583 | 0.94 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BRAB9A | |
| SCHEMBL3055019 | 0.94 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BRAB9A | |
| SCHEMBL302596 | 0.94 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BRAB9A | |
| SCHEMBL3052051 | 0.94 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BRAB9A | |
| SCHEMBL7171003 | 0.94 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BRAB9A | |
| SCHEMBL3051371 | 0.94 | MAPT (0.74) | MAPTTP53TSHRPLA2G4BRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921309-B2 | Lipopeptide compounds and their use | UNIQUEST PTY LIMITED (AU) | 2014-12-30 | — | — | US | disclosed |
| EP-2350119-B1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | UNIQUEST PTY LTD (AU) | 2014-10-29 | — | — | EP | disclosed |
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | MERLION PHARMACEUTICALS PTE LTD (SG) | 2011-09-15 | — | — | US | disclosed |
| EP-2350119-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | Merlion Pharmaceuticals Pte Ltd. (SG) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010062264-A1 | LIPOPEPTIDE COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224129-A1 | Lipopeptide Compounds and Their Use | VIP, LTA, CLPTM1 | MAPT 4432/4885TP53 3875/4885TSHR 2537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.